Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01340209
First received: April 13, 2011
Last updated: July 24, 2013
Last verified: July 2013
  Purpose

The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat inhaler will be examined on top of maintenance treatment with inhaled corticosteroid controller medication in patients with moderate to severe persistent asthma. Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma exacerbations, effects on asthma control, and number of adverse events.


Condition Intervention Phase
Asthma
Drug: Tiotropium Respimat
Drug: Placebo Respimat
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • In this trial, no primary endpoints of efficacy are defined because the primary objective of this trial is to evaluate the long term safety of tiotropium (secondary endpoint below) delivered via the Respimat inhaler in the patients with asthma. [ Time Frame: This endpoint has no specific timeframe ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Laboratory data at all visits except Visits 2, 3A, 4A/B, 5A/B, and 6A/B/C during treatment period. Haemoglobin, ¿ Total serum IgE [ Time Frame: 4, 12, 24, 36 and 52 weeks ] [ Designated as safety issue: No ]
  • 12-lead electrocardiogram (ECG). [ Time Frame: 52 week ] [ Designated as safety issue: No ]
  • Trough FEV1 response and trough forced vital capacity (FVC) at all visits except Visit 3, 3A, 4A/B, 5A/B, and 6A/B/C of the 52-week treatment period. [ Time Frame: 12, 24, 36 and 52 weeks ] [ Designated as safety issue: No ]
  • Individual in-clinic peak expiratory flow (PEF) measurements during the 52-week treatment period (Trough PEF). [ Time Frame: 12, 24, 36 and 52 weeks ] [ Designated as safety issue: No ]
  • PEF variability: PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values (weekly means will be compared) during the 52-week treatment period. [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
  • PEF AM/PM: change from baseline in mean weekly morning and pre-dose evening PEF respectively measured by patients at home during the 52-week treatment period. [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
  • Use of pro re nata (PRN) salbutamol HFA MDI rescue medication during the 52-week treatment period: number of actuations of rescue therapy used per day (i.e. the full 24 hour period, the daytime and the night time; weekly means will be compared). [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
  • Asthma symptoms as assessed by the patient's eDiary during the 52-week treatment period. Analysis with regard to daytime and nocturnal symptoms will be done. [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
  • All adverse events [ Time Frame: Day 0 until end of follow up (59 weeks) ] [ Designated as safety issue: No ]
  • Vital signs: pulse rate (beats/min) and blood pressure (seated, mmHg) recorded not only in conjunction with spirometry but also all records performed at all visits during treatment period. [ Time Frame: 0, 4, 12, 24, 36 and 52 weeks ] [ Designated as safety issue: No ]
  • Vital status information (dead or alive) of prematurely discontinued patients [ Time Frame: Planned date follow up visit (59 weeks) ] [ Designated as safety issue: No ]

Enrollment: 285
Study Start Date: April 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tiotropium Respimat (low dose)
Tiotropium low dose once daily delivered with Respimat inhaler
Drug: Tiotropium Respimat
Tiotropium low dose once daily delivered with Respimat inhaler
Experimental: Tiotropium Respimat (high dose)
Tiotropium high dose once daily delivered with Respimat inhaler
Drug: Tiotropium Respimat
Tiotropium high dose once daily delivered with Respimat inhaler
Placebo Comparator: Placebo Respimat
Tiotropium placebo once daily delivered with Respimat inhaler
Drug: Placebo Respimat
Tiotropium placebo once daily delivered with Respimat inhaler

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. All patients including the patients under age (under 20 years old) must sign and date an Informed Consent Form consistent with ICH-GCP guidelines and Good Clinical Practice (GCP) prior to participation in the trial [i.e. prior to any trial procedures, including any pre-trial washout of medications and medication restrictions for pulmonary function test (PFT) at Visit 1]. Regarding patients under age, a guardian or a legally authorised representative must also sign and date an Informed Consent Form.
  2. Male or female outpatients aged at least 18 years but not more than 75 years at Visit 0.
  3. All patients must have at least a 12-week history of asthma at the time of enrolment (Visit 0) into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling inclusion criterion 5.
  4. The initial diagnosis of asthma must have been made before the patient's age of 40.
  5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator reversibility (15-30 minutes after 400 µg salbutamol) resulting in a Forced Expiratory Volume in one second (FEV1) increase of at least 12% and at least 200 mL .
  6. All patients must have been on maintenance treatment with a medium, stable dose of inhaled corticosteroids (ICS) [alone or in a fixed combination with a Long-acting beta-adrenergic (LABA)] for at least 4 weeks prior to Visit 1.
  7. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of at least 1.5.
  8. All patients must have a pre-bronchodilator FEV1 at least 60% and less than or equal to 90% of predicted normal at Visit 1.
  9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year (52 weeks) prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack years.
  10. Patients must be able to use the Respimat inhaler correctly, which is judged at the discretion of the investigator..
  11. Patients must be able to perform all trial related procedures including technically acceptable PFTs and use of electronic diary (eDiary)/peak flow meter, which is judged at the discretion of the investigator.

Exclusion criteria:

  1. Patients with a significant disease other than asthma. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
  2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood chemistry if the abnormality defines a significant disease as defined in exclusion criterion no 1.
  3. Patients with a recent history (i.e. 6 months or less) of myocardial infarction prior to Visit 0.
  4. Patients who have been hospitalised for cardiac failure during the past year prior to Visit 0.
  5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year prior to Visit 0.
  6. Patients with lung diseases other than asthma (e.g. COPD).
  7. Patients with known active tuberculosis.
  8. Patients with malignancy and/or patients who have undergone resection, radiation therapy or chemotherapy for malignancy within the last 5 years prior to Visit 0. Patients with treated basal cell carcinoma are allowed.
  9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 1.
  10. Patients with significant alcohol or drug abuse, which is judged at the discretion of the investigator, within the past 2 years prior to Visit 0.
  11. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the study medication delivery systems.
  12. Pregnant or nursing women.
  13. Women of childbearing potential not using a highly effective method of birth control.
  14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.
  15. Patients who have been treated with beta-blocker medication within four weeks prior to Visit 1 and/or during the screening period. Topical cardio-selective beta-blocker eye medications for non-narrow angle glaucoma are allowed.
  16. Patients who have been treated with the long-acting anticholinergic tiotropium (Spiriva) within four weeks prior to Visit 1 and/or during the screening period.
  17. Patients who have been treated with oral beta-adrenergics within four weeks prior to Visit 1 and/or during the Screening period.
  18. Patients who have been treated with systemic corticosteroids within four weeks prior to Visit 1 and/or during the screening period.
  19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®), within 6 months prior to Visit 1 and/or during the screening period.
  20. Patients who have been treated with other non-approved and according to international guidelines not recommended "experimental" drugs for routine asthma therapy within four weeks prior to Visit 1 and/or during the screening period.
  21. Patients with any asthma exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 and/or during the screening period.
  22. Patients who are currently participating in another trial.
  23. Patients with narrow-angle glaucoma and/or micturition disorder due to prostatic hyperplasia.
  24. Patients with below 80% of the eDiary completion compliance on Visit 2 (diary compliance of at least 80% is required).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01340209

  Show 55 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Pfizer
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01340209     History of Changes
Other Study ID Numbers: 205.464
Study First Received: April 13, 2011
Last Updated: July 24, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Tiotropium
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2014